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Abstract Background Early graft occlusion due to thromboembolic events is a well-known
complication after coronary artery bypass grafting (CABG). Fibrinogen, the coagulation
factor I, is a glycoprotein that is transformed by thrombin into fibrin. It plays a major role
in thrombus formation and is highly elevated after CABG. Our aim was to determine if
postoperative lowering of fibrinogen levels by H.E.L.P. (heparin-mediated extracorporeal
low-density lipoprotein [LDL] fibrinogen precipitation) aphaeresis could reduce the rate
of early graft occlusion in patients with hypercholesterolemia undergoing CABG.
Methods Between December 2004 and September 2009, 36 male patients with
hypercholesterolemia (mean LDL cholesterol 128  12mg/dL), mean age 58  9 years,
underwent CABG. Mean preoperative fibrinogen level was 387  17 mg/dL. H.E.L.P.
aphaeresis was postoperatively performed when fibrinogen levels exceeded 350 mg/dL
on day 1 and 250 mg/dL every consecutive day up to day 8. Pre- and postaphaeresis
blood samples were obtained and plasma fibrinogen level reduction was calculated.
Early graft occlusion was evaluated by means of coronary angiography or multislice
computed tomography before discharge.
Results A total of 128 distal anastomoses were performed in 36 patients (mean 3.6/
patient). Postoperatively, 191 H.E.L.P. aphaeresis sessions were performed (mean 5.3/
patient). Fibrinogen levels were lowered from 391  10 mg/dL (preaphaeresis) to
171  5 mg/dL (postaphaeresis; p < 0.001). Coronary angiography (multislice com-
puted tomography in 7 patients) revealed graft patency in 125 of 128 grafts (98%
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Early graft occlusion after coronary artery bypass grafting
(CABG) affects 15 to 25% of the grafts within 1 year after the
operation,1–3 andmostof thembecomeoccludedwithin thefirst
month.3,4 Only 60% of vein grafts remain patent after 10 years.
Early graft failure negatively influences long-term survival and
freedom from myocardial infarction and redo CABG.5 Many
factors can lead to early bypass graft occlusion, but recently
published work showed an increased preoperative fibrinogen
level as a main predictor of both early graft occlusion and late
cardiovascular events.6 Fibrinogen, the coagulation factor I, is a
glycoprotein that is transformed by thrombin into fibrin. It plays
amajor role in clot formation and is highly elevated after cardiac
surgery as an acute phase protein.7
Heparin-mediated extracorporeal low-density lipoprotein
(LDL)/fibrinogen precipitation (H.E.L.P.) apheresis is an estab-
lishedmethod to decrease LDL cholesterol, and as a side effect
fibrinogen levels are reduced by50 to 70%.8 In this prospec-
tive single-center study, we sought to determine if postoper-
ative reduction of fibrinogen levels by H.E.L.P. aphaeresis
improves early bypass graft patency after CABG.
Materials and Methods
Patient Characteristics and Primary Study Goals
BetweenDecember 2003 and September 2008, 36male patients
(mean age 58  9 years) underwent CABG and postoperative H.
E.L.P. apheresis. All patients had hypercholesterolemia (mean
LDL cholesterol 128  12 mg/dL) and three-vessel coronary
disease. Patient demographics are given in ►Table 1. The
patients were on standard postoperative medication consisting
of aspirin, β-blocking agents, and statins.
Thirty-four patients received cardiopulmonary bypass
using antegrade cardioplegia and mild hypothermia, and
two patients underwent off-pump revascularization. For
cardiopulmonary bypass, heparin (300 IU/kg) was admin-
istered to achieve an activated clotting time exceeding 400
seconds. Patients who were operated with the off-pump
technique received 150 IU/kg, and activated clotting time
was kept above 200 seconds while the anastomosis was
performed. After standardmedian sternotomy, the thoracic
internal artery and saphenous vein graft as well as radial
artery (RA) grafts were harvested. The vein grafts were
tested and slightly distendedwith Ringer’s acetate, checked
for leakage, and stored at room temperature. The thoracic
internal and radial arteries were kept in papaverine gauze
until implantation. Distal anastomoses were performed
with 7–0 or 8–0 Prolene (Ethicon; Somerville, New Jersey,
United States). Proximal anastomoses were done with 6–0
or 7–0 Prolene running sutures with the help of a side-
biting clamp. In three veins and two radial arteries, the
HEARTSTRING device (Maquet GmbH, Rastatt, Germany)
was used. The graft flow was assessed intraoperatively by
transit time measurement routinely. Acetylsalicylic acid
was administered from postoperative day 1 on. The prima-
ry outcome measures of the study were reduction of
fibrinogen and early graft patency. Several laboratory val-
ues were measured, which are not the subject of this study.
Side effects and postoperative complications of the therapy
were documented. All patients gave written informed
consent.
H.E.L.P. Aphaeresis Procedure
The H.E.L.P. system (Plasmat Futura, B. Braun, Melsungen,
Germany) basically operates by increasing positive charges
on LDL cholesterol and lipoprotein(a) (Lp[a]) molecules at
a pH of 5.12 when a network of heparin and fibrinogen is
formed. A detailed description of the process has been
published previously.9 Briefly, venous blood is drawn
from a central venous line or a cubital vein, and plasma is
obtained by a plasma separator and mixed continuously
with an acetate-heparin buffer (pH 4.85). The precipitation
of fibrinogen, LDL, and Lp(a) occurs immediately, and the
suspension is circulated through a polyethersulfone mem-
brane to remove the precipitate. Excess heparin is adsorbed
by an anion-exchange filter, physiologic pH is restored by
bicarbonate dialysis, and extra fluid is removed by ultrafil-
tration. Finally, plasma ismixedwith the red blood cells and
returned to the patient, as shown in►Fig. 1. A single H.E.L.P.
session takes about 1 hour, and 3 to 3.5 L of plasma are
treated.
Table 1 Demographic data
Patients (n) 36
Age (y), mean 58  9
Male (n) 36 (100%)
Coronary three-vessel-disease (n) 36 (100%)





Previous myocardial infarction 16 (21%)
aphaeresis-related complications were limited to hypotensive episodes in two patients
and bacteremia in one patient.
Conclusions H.E.L.P. apheresis offers an easy, save, and efficient method to decrease
fibrinogen postoperatively in patients having CABG. Showing excellent graft patency
rates in comparison to the literature, this method is a promising tool to reduce early
graft occlusion after CABG.
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Blood Samples
Blood was drawn from each patient before surgery and on
every postoperative day up to day 8. Thefibrinogen levelswere
measured in citrate plasma using themethod of Clauss (STA-R,
Roche, Basel, Switzerland). H.E.L.P. aphaeresis was performed
when the fibrinogen levels exceeded 350 mg/dL on the first
postoperative day and 250 mg/dL on every consecutive day.
Pre- and postaphaeresis differences were calculated.
Statistical Analysis
All analyses were performed using the SPSS software (version
15.0 for Windows, SPSS, Inc., Chicago, Illinois, United States).
Statistical descriptive analyses of the results are presented as
mean values  standard deviations. The analytical studies were
performed by analysis of variance. A post hoc Tukey test for
normally distributed valueswas used for posterior comparisons.
A p value less than 0.05 was considered statistically significant.
Results
Operative Data
A total of 128 bypasses were performed in 36 patients (3.6
grafts/patients). The type and graft distribution are shown
in ►Table 2. The left internal thoracic artery (LITA) was
anastomosed sequentially to the left anterior descending
and a diagonal branch in 1 case, the RA as a T-graft proximally
to a vein was anastomosed to a LITA in 1 case, the right
internal thoracic artery (RITA) as a T-graft was proximally
anastomosed to the LITA in 2 cases, and 1 free right internal
thoracic artery was directly connected to the aorta.
H.E.L.P. Aphaeresis
One hundred ninety-one aphaeresis sessions were necessary
(5.3/patient) in our study population.►Fig. 2 demonstrates the
Fig. 1 Schematic description of the heparin-mediated extracorporeal LDL fibrinogen precipitation aphaeresis procedure. Abbreviations: LDL, low-
density lipoprotein; Lp(a), lipoprotein(a).
Table 2 Perioperative data regarding coronary revascularization
(bypass graft, target vessel)
Target vessel
(coronary artery)
LITA RITA RA Saphenous
vein graft
LAD 29 0 0 4
RCX 0 2 0 12
RCA 0 4 8 17
Diagonal branch 3 2 3 19
Marginal branch 0 9 5 11
Total 32 17 16 63
Abbreviations: LAD, left anterior descending; LITA, left internal thoracic
artery; RCA, right coronary artery; RCX, ramus circumflexus; RITA, right
internal thoracic artery.
Fig. 2 Levels of fibrinogen (mg/dL) before and after heparin-mediated
extracorporeal low-density lipoprotein fibrinogen precipitation (HELP)
aphaeresis.
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preoperative as well as pre- and postaphaeresis fibrinogen
levels. Of note, the peak on postoperative day 2 is explained
by the fact that patients with a level below 350 mg/dL on
postoperative day 1 (e.g., 340 mg/dL) show extremely high
fibrinogen levels the following day, resulting in a mixture of
very high levels of those who did not have H.E.L.P. therapy on
postoperative day 1 and those who did. Fibrinogen levels were
reduced from a mean of 391  10 mg/dL (preaphaeresis) to a
mean of 171  5 mg/dL (postaphaeresis), as shown in ►Fig. 2
(p < 0.001)—a 220 mg/dL or 52% mean reduction of fibrinogen
per session.
Bypass Graft Patency
Bypass graft patency was evaluated by conventional angiog-
raphy in 29 patients and bymultislice computed tomography
(64-slice) in 7 patients after 11  9 days. Two independent
experienced investigators read the scans and judged the
bypasses patent or occluded. The total bypass patency rate
was 98% (125/128 grafts). All 32 LITA, 17 RITA, and 16 RA
grafts were patent, and 3 vein grafts to diagonal andmarginal
targets of 1.5-mm diameter were occluded, reflecting a 100%
patency rate for arterial grafts and a 95% patency rate for
venous grafts (►Table 3). The occluded vein grafts were
performed under cardioplegic arrest.
Postoperative Complications
Postoperative complications are listed in ►Table 4. The 30-
day mortality was 0%. No patient suffered from new myocar-
dial infarction or from stroke. Pericardial effusion, a possible
H.E.L.P.-related heparin-mediated effect, occurred in 2 pa-
tients. One patient showed either a sternal dehiscence or
pneumonia, and 4 patients had new-onset atrial fibrillation,
which converted in sinus rhythm after appropriate medica-
tion. Signs of infectionswere highly suspicious for bacteremia
due to the central venous line in 1 patient. The catheter was
removed and further aphaeresis was done via a cubital vein.
Discussion
Early graft occlusion is a known complication after CABG. The
graft patency of bypass grafts in coronary surgery may
depend on multiple factors, including age, sex, the quality
of the grafts and target vessels, and even components of the
coagulation cascade.1 The thromboembolic occlusion of the
bypass graft occurs at a frequency of 5 to 15%, depending on
the graft utilized.1–3 Fibrinogen is one component leading to
early graft occlusion. As described by Blessing et al, fibrinogen
is a substrate of thrombus formation that plays amajor role in
both primary and secondary hemostasis.8,9 The surgical
trauma itself initiates the acute-phase response and also
activates the coagulation and clot formation. These factors
may lead to high fibrinogen levels of up to 600 mg/dL during
the early postoperative period, providing an impaired hem-
orheological pattern that promotes thrombus formation.
The general acceptance of fibrinogen as an important risk
factor for acute cardiovascular syndromes is rather low. How-
ever, as described by Jaeger et al,10 evidence from a recentmeta-
analysis formed by 22 studies of 63,736 subjects and 5,717
events suggests that the risk formyocardial infarction and stroke
is almost twice as high if the fibrinogen level exceeds 3.03 g/L,
with an odds ratio of 1.99 and a 95% confidence interval of 1.85
to 2.13. The predictive value of fibrinogen levels equally applies
to men andwomen independent of age and primary or second-
ary prevention. As emphasized by Jaeger et al, repeated fibrino-
genmeasurements are extremely useful specifically in high-risk
patients.10 In combination with classical cardiovascular risk
factors such as hypertension, hypercholesterolemia, or diabetes,
the risk of acute cardiovascular syndromesmay further increase
by 6- to 12-fold, and fibrinogen remains an independent risk
factor for both cardiac and cardiovascular atherothrombotic
complications, specifically the vulnerable plaque formation, as
well as for complications after interventional or surgical treat-
ment. Fibrinogen and its effector protein thrombin substantially
determine the extent and outcome of atherothrombotic com-
plications, because they are the molecules linking the mutually
atherosclerotic events, coagulation/fibrinolysis, rheology/vaso-
tonus, and inflammation.9,11 In our patients, the fibrinogen
levels could be postoperatively reduced by up to 50% per session.
In our opinion, this reduction may be in part responsible for the
graft patency rates of our coronary bypasses.
Additionally, several studies reported a cumulative effect of
fibrinogen and LDL cholesterol. Interventional studies on fibri-
nolytic and defibrinating substances have confirmed the benefit
of fibrinogen reduction and extended the experimental
Table 3 Perioperative patency diagnostics for bypass surgery
Angiography (n) 29 (81%)
MSCT (n) 7 (19%)
Total 36 (100%)
Patency
LITA (n) 32/32 (100%)
RITA (n) 17/17 (100%)
RA (n) 16/16 (100%)
SVG (n) 60/63 (95%)
Total (n) 125/128 (98%)
Abbreviations: LITA, left internal thoracic artery; MSCT, multislice
computed tomography; RA, radial artery; RITA, right internal thoracic
artery; SVG, saphenous vein graft.
Table 4 Postoperative outcome
Death (n) 0 (0%)
Perioperative MI (n) 0 (0%)
Stroke (n) 0 (0%)
Pericardial effusion (n) 2 (6%)
Sternal dehiscence (n) 1 (3%)
Pneumonia (n) 1 (3%)
Atrial fibrillation (n) 4 (12%)
Bacteremia (n) 1 (3%)
Abbreviation: MI, myocardial infarction.
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evidence for the relevance of fibrinogen in the pathogenesis of
these syndromes. Accordingly, the preventive use of fibrates
leading to moderate reductions in plasma cholesterol and
fibrinogen significantly diminished the rate of reinfarction.9
Biochemically, the composition of newly formed LDL particles
after aphaeresis is described to be altered: LDL particles isolated
after LDL aphaeresis had an increased resistance to oxidative
stress invitro.12 In addition, antioxidants arenotdepletedby LDL
aphaeresis. The extracorporeal method itself does not have a
negative impact on the oxidative/antioxidative balance. A recent
investigation showed that LDL cholesterol had a more pro-
nounced effect on blood rheology than fibrinogen.13,14
The emerging possibilities of a >50% fibrinogen reduction
as noted by studies using H.E.L.P. aphaeresis strengthen the
therapeutic concept of eliminating the blood risk factors—as
effective as it can be—to achieve an optimal plaque
regression.15
Conclusion
Early and extensive fibrinogen aphaeresis is a safe and very
effective extracorporeal treatment to influence the outcome
after CABG as shown in this study. Thefibrinogen levels can be
reduced by more than 60% by using aphaeresis. Additionally,
LDL, Lp(a), and C-reactive protein can be reduced by this
method. Furthermore, adhesion molecules and activities of
inflammatory cells were also found to be reduced after a
single aphaeresis session. This method demonstrates a novel
therapeutic approach for preventing early graft occlusion in
patients undergoing multivessel CABG.
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